CorPath200 Detroit Medical Center Cardiovascular Institute

The Detroit Medical Center (DMC) announced that a team of heart specialists at its Cardiovascular Institute (CVI) has successfully conducted the Midwest's first-ever "robotic-assisted" coronary revascularization to relieve heart artery blockages.  The successful implementation of the pioneering new treatment procedure — unique in Michigan and so far performed at only three institutions in the United States — means that DMC heart care patients now have access to the world's most advanced treatment method for relieving  blockages in heart arteries, said CVI President Theodore L. Schreiber, M.D.

January 11, 2013 — Guided Interventions LLC, a startup company developing new, easier to use fractional flow reserve (FFR) a product to help cardiologists better assess the physiological impact of coronary artery blockages, has received a $250,000 investment commitment from nonprofit venture development organization JumpStart Inc.

 

In a recent LinkedIn Medical Device Group posting, it was noted that DuVal & Associates, P.A. filed a Citizen Petition and Petition for Stay of Action with the FDA, on behalf of the Minnesota Medical Device Alliance (MMDA). See: http://medgroup.biz/FDA-petition

Angioslide announced the closing of $6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments to complete the round.

The results of a recent study presented yesterday at the American Heart Association Scientific Sessions 2012 conference in Los Angeles showed that a high-quality single-lead ECG can be quickly and easily recorded using an iPhone with the AliveCor medical device and application to diagnose atrial fibrillation (AF).

CardiAQValve Technologies Inc. received $37.3 million in funding in its second round of equity financing. OrbiMed led the round and was joined by Versant Ventures, Advent Life Sciences and existing investors. The funding, which incorporates conversion of a 2011 bridge financing, will be used to further validate the company’s transcatheter mitral valve implantation (TMVI) technology and is expected to carry the company through its feasibility and CE mark clinical trials. Concurrent with the financing, David Bonita, M.D., and Vince Burgess have joined the board of directors representing OrbiMed.

Spectranetics Corp. announced an agreement to purchase the assets of Upstream Peripheral Technologies Ltd., an affiliate of Aran Research Development and Prototypes Ltd. Included in the acquisition are unique technologies that expand Spectranetics' vascular intervention portfolio. A full launch in the United States and Europe will occur in February 2013.

Abbott Absorb bioresorbable stent

Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of Abbott's drug-eluting Absorb boresorbable vascular scaffold (BVS) device to the company's Xience family of drug-eluting stents.

 

At RSNA 2012, GE Healthcare announced a first-of-its-kind agreement with the University of Wisconsin (UW) School of Medicine and Public Health for the purpose of providing physicians with more tools to optimize radiation dose, take clinically-useful images, and potentially reduce the frequency of repeat computed tomography (CT) scans.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now